EP Patent

EP2613794A1 — Treatment of constipation-predominant irritable bowel syndrome

Assigned to Forest Laboratories Holdings ULC · Expires 2013-07-17 · 13y expired

What this patent protects

The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.

USPTO Abstract

The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.

Drugs covered by this patent

Patent Metadata

Patent number
EP2613794A1
Jurisdiction
EP
Classification
—
Expires
2013-07-17
Drug substance claim
No
Drug product claim
No
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.